Connect Biopharma is trading at $1.15, down 5.76%, as investors continue reacting to the Phase 2 Seabreeze STAT asthma trial missing statistical significance on its primary Day 28 treatment-failure endpoint.
- Rademikibart produced a 66% reduction versus placebo and statistically significant lung-function improvement.
- The stock fell 7.95% to $1.22 on September 22, extending the post-results selloff; broader biotech strength has not offset the company-specific clinical disappointment.